Come together
New NHS care models and CCG mergers require an innovative, partnership approach from pharma
PharmaTimes -
January/February 2018
A new year brings new challenges for pharma, but just as many – if not more – opportunities.
With the EMA moving (see p20) and Brexit, as ever, on the horizon, one of the most pressing questions hanging over pharma’s head as we enter 2018 is the issue of recruitment. Is the talent pool about to dry up, or are recent investments by big companies a sign that things are on their way up? We investigate on p31.
Looking further to the future, 3D printing just might be one of the most exciting technological developments for the industry, even if it’s some way off, and on p22 we look at the myriad possibilities of printing personalised drugs. Tech can also play an important role in getting patients to adhere to drugs, as we find out on p19.
Meanwhile, on p35 we take a look at recent trends in pharma’s patient-centricity and social responsibility efforts and get some advice on how to best approach such initiatives from those who have spearheaded them.
I hope you enjoy the issue.
January 2018 - magazine highlights
How much do we really understand the patient?
New approaches to studying adherence
Easing the burden
A guide to best practices in conducting rare disease trials
Going Dutch
How pharma regulation could change after the European Medicines Agency moves from London to Amsterdam
3D printing drugs: more precise, more personalised
Printing out your own medicines is a long way off, but the possibilities are truly exciting
The changing face of post-marketing research
A look at the rise of real-world evidence and humanistic patient reported outcomes
Loud and clear
We asked the winning companies from the 2017 Communications Team of the Year competition what pharma’s comms priorities should be
Finding pharma's future
With pharma changing rapidly and Brexit on the horizon, where is recruitment heading?
Beyond 'beyond the pill'
How pharma companies can take patient-centricity and social responsibility a step further
Rare opportunity
Inside the world of rare diseases with Joe Wiley, CEO of Amryt Pharma
Patient Files: Schizophrenia
PharmaTimes talks to Andrew Voyce about his experiences with the mental disorder
